Newsfeeds - Spark Newswire

1 minute read

5 Stocks To Watch For December 20, 2021

Today, 5:48 PM

Some of the stocks that may grab investor focus today are: Wall Street expects Carnival Corporation (NYSE: CCL) to report a quarterly loss at $1.27 per share on revenue of $1.34 billion before the opening bell. Carnival shares slipped 0.4% to $18.20 in after-hours trading.

ARGX

2 minute read

The Week Ahead In Biotech (Dec. 19-25): Amgen And Aquestive Regulatory Decisions Key Events Of Holiday-Shortened Week

By Shanthi Rexaline

Today, 5:48 PM

Biotech stocks reversed course and advanced solidly in the week ending Dec. 17, as an increase in risk aversion pushed investors to buy into defensive stocks. The sector also drew strength from some positive stock-specific news.

AMGN

1 minute read

argenx Shares Were Halted Earlier; Now Seeing Report FDA Approves Co.’s Vyvgart For Treatment Of Generalized Myasthenia Gravis

By Benzinga Newsdesk

Today, 5:48 PM

https://twitter.com/adamfeuerstein/status/1471958009853132801

ARGX

4 minute read

The Daily Biotech Pulse: Genfit Spikes On Liver Disease Drug Licensing Deal, Lyell Gets Nod For Solid Tumor Study, Decision-Day For Intra-Cellular, Argenx

By Shanthi Rexaline

Today, 5:48 PM

Here's a roundup of top developments in the biotech space over the last 24 hours.

ALVR

2 minute read

2 Mid-Cap Biopharma Stocks BofA Securities Recommends For 2022

By Shanthi Rexaline

Today, 5:48 PM

Biotech stocks are risky investments and to make a profit informed decision-making is needed. BofA Securities announced its top mid-cap biopharma picks in a note released Tuesday.

ALNY

3 minute read

The Week Ahead In Biotech (Dec. 12-18): Hematology Conference Presentations, FDA Decisions For Calliditas, Argenx, Intra-Cellular & Eagle Pharma And More

By Shanthi Rexaline

Today, 5:48 PM

Biotech stocks closed out the week ending Dec. 10 with modest losses as investors moved money out of defensives and into risky bets amid the broader market rebound.

ABBV

1 minute read

Analyst Ratings

Analyst Ratings For argenx

By Benzinga Insights

Today, 5:48 PM

Analysts have provided the following ratings for argenx (NASDAQ:ARGX) within the last quarter:

ARGX

7 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For December 8, 2021

By Benzinga Insights

Today, 5:48 PM

ALLE

6 minute read

Attention Biotech Investors: Mark Your Calendar For December PDUFA Dates

By Shanthi Rexaline

Today, 5:48 PM

A majority of verdicts handed down by the FDA in November were positive. Three new molecular entities were approved during the month, taking the total number of NME approvals for the year-to-date period to 45. This is just one short of NME approvals received for the same period last year.

ABBV

1 minute read

10 Biggest Price Target Changes For Monday

By Lisa Levin

Today, 5:48 PM

Citigroup cut Merck & Co., Inc. (NYSE: MRK) price target from $105 to $85. Merck shares fell 2% to $77.55 in pre-market trading.

ABEO